Research Article
Effects and Safety of the Tripterygium Glycoside Adjuvant Methotrexate Therapy in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Table 1
Characteristics of the included RCTs.
| | Study ID | Patients | Treatment | Control | Primary outcomes | Secondary outcomes | Course of treatment (months) | | Intervention | N | M/F | Age (Mean ± SD) | Dose(mg/d) | Intervention | N | M/F | Age(Mean ± SD) | Dose(mg/w) |
| | Wang 2013 | Patients with RA | TG + MTX | 76 | — | 43.4 ± 6.6 | +TG (30) | MTX | 50 | — | 43.4 ± 6.6 | 15 | ①② | ④⑤⑥⑦⑧ | 3 | | Feng 2013 | Patients with RA | TG + MTX | 22 | 2/18 | 51 ± 4.2 | +TG (60) | MTX | 20 | 2/18 | 52 ± 3.8 | 10 | ① | ④⑤⑥⑦ | 3 | | Yang 2013 | Patients with EORA | TG + MTX | 40 | 6/34 | 69.3 ± 6.9 | +TG (30) | MTX | 40 | 4/36 | 68.8 ± 7.4 | 10 | ①② | ④⑤⑥⑦⑧ | 6 | | Zhang 2015 | Patients with EORA | TG + MTX | 66 | 6/54 | 65 ± 4.2 | +TG (60) | MTX | 60 | 6/54 | 65 ± 3.8 | 10 | ① | ④⑤⑥⑦ | 3 | | Lin 2016 | Patients with RA | TG + MTX | 50 | 19/31 | 44.05 ± 4.9 | +TG (30) | MTX | 50 | 20/30 | 43.7 ± 5.3 | 10 | ①②③ | ④⑤⑥⑦⑧ | 6 | | Zhou 2017 | Patients with RA | TG + MTX | 56 | — | 45.7 ± 4.8 | +TG (60) | MTX | 56 | — | 45.7 ± 4.8 | 10 | ①② | ④⑤⑥⑦⑧ | 3 | | Lv 2015 | Patients with RA | TG + MTX | 69 | 14/55 | 50.6 | +TG (60) | MTX | 69 | 10/59 | 51.0 | 7.5–12.5 | ①②③ | ④⑤⑥⑦ | 6 | | Zhou 2018 | Patients with RA | TG + MTX | 69 | 14/55 | 50.6 | +TG (60) | MTX | 69 | 10/59 | 51.0 | 7.5–12.5 | ①②③ | ④⑤⑥⑦ | 6 | | Wang 2018 | Patients with RA | TG + MTX | 15 | 7/8 | 55.5 | +TG (60) | MTX | 15 | 7/8 | 53.7 | 7.5–12.5 | ② | ④⑤⑥⑦ | 3 |
|
|
Notes: EORA: elderly-onset rheumatoid arthritis ①: ACR20; ②: ACR50; ③: ACR70; ④: SJC; ⑤: TJC; ⑥: ESR; ⑦: CRP; ⑧: RF.
|
